2024-12-14 04:23:34
European Central Bank President Lagarde: The inflation problem has not yet been completed. European Central Bank President Lagarde said that the inflation problem has not yet been completed and the anti-inflation task has not yet ended, but inflation is moving towards the goal.European Central Bank President Lagarde: Since July 2023, the flexibility of the Emergency Anti-epidemic Bond Purchase Program (PEPP) has not been used, and the transmission protection tool (TPI) has not been discussed.Market news: STARBOARD VALUE shares in bitcoin mining company RIOT.
Royal Bank of Canada: The European Central Bank may move towards negative real interest rate. Royal Bank of Canada BlueBay Asset Management said that the European Central Bank may cut the interest rate below 2% next year, which the agency estimated to be a short-term neutral interest rate. Kaspar Hense, senior portfolio manager of the institution, said in a report that the core inflation rate is expected to be around 2.5% in the first half of 2025, which means that the real interest rate will be negative. He said that under the influence of unfavorable factors such as trade, continuous competitive pressure from other countries and financial problems, this should play a moderate supporting role in the economy.Novo Nordisk: After the clinical trial results of kidney therapy were released, European regulators gave Ozempic a positive label evaluation.Spot gold fell by $5 in the short term and is now reported at $2,704 per ounce.
The promotion of "Investing in China" in the Middle East was held in the United Arab Emirates, and the promotion of "Investing in China" in the Middle East and the docking of industrial capital between China and the Middle East were held in Abu Dhabi, the capital of the United Arab Emirates, from 11th to 12th. 40 China enterprises from the fields of new energy, advanced manufacturing, biomedicine, information technology, etc. negotiated and docked with more than 70 sovereign wealth funds and investment institutions in the Middle East.According to HKEx documents, iFLYTEK Medical Technology Co., Ltd. passed the listing hearing of HKEx.Baiyang Pharmaceutical Group signed an agreement with Peking University Hospital. On December 12, Baiyang Pharmaceutical Group signed a cooperation agreement with Peking University No.1 Hospital, and obtained the exclusive right to patent, clinical development and registration, production and marketing of "targeted integrin small molecule inhibitor" in Peking University Hospital.
Strategy guide
12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide
12-14